OncLive® On Air
By OncLive® On Air
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by OncLive® On Air
Category: Health & Fitness
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 2
Reviews: 0
Episodes: 488
Description
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
| Episode | Date |
|---|---|
|
S10 Ep30: Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
|
May 13, 2024 |
|
S10 Ep30: Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors
|
May 09, 2024 |
|
S10 Ep30: Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma
|
May 06, 2024 |
|
S10 Ep29: Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
|
May 02, 2024 |
|
S10 Ep28: Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
|
Apr 29, 2024 |
|
S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
|
Apr 22, 2024 |
|
S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
|
Apr 18, 2024 |
|
S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
|
Apr 11, 2024 |
|
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
|
Apr 08, 2024 |
|
S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management
|
Apr 01, 2024 |
|
S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
|
Mar 28, 2024 |
|
S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
|
Mar 25, 2024 |
|
S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas
|
Mar 21, 2024 |
|
S10 Ep20: Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
|
Mar 18, 2024 |
|
S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
|
Mar 11, 2024 |
|
S10 Ep18: Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
|
Mar 07, 2024 |
|
S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
|
Feb 29, 2024 |
|
S10 Ep16: Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS
|
Feb 26, 2024 |
|
S10 Ep15: Tripathy Talks Through the Enduring Impact of the Miami Breast Cancer Conference
|
Feb 22, 2024 |
|
S10 Ep14: Kitco and Patel Emphasize the Importance of GVHD Research and Awareness
|
Feb 19, 2024 |
|
S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma
|
Feb 12, 2024 |
|
S10 Ep12: Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
|
Feb 08, 2024 |
|
S10 Ep11: Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment
|
Feb 05, 2024 |
|
S10 Ep10: Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
|
Jan 29, 2024 |
|
S10 Ep9: FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL
|
Jan 25, 2024 |
|
S10 Ep8: Lunning and Maddocks Talk Through Frontline MCL Management
|
Jan 22, 2024 |
|
S10 Ep7: FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
|
Jan 15, 2024 |
|
S10 Ep6: Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
|
Jan 11, 2024 |
|
S10 Ep5: Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
|
Jan 08, 2024 |
|
S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
|
Jan 04, 2024 |
|
S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
|
Jan 01, 2024 |
|
S10 Ep2: Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL
|
Dec 28, 2023 |
|
S10 Ep1: Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
|
Dec 25, 2023 |
|
S9 Ep50: Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
|
Dec 21, 2023 |
|
S9 Ep49: Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
|
Dec 18, 2023 |
|
S9 Ep48: Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions
|
Dec 11, 2023 |
|
S9 Ep47: Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer
|
Dec 07, 2023 |
|
S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Dec 04, 2023 |
|
S9 Ep45: Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
|
Nov 30, 2023 |
|
S9 Ep44: Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors
|
Nov 23, 2023 |
|
S9 Ep43: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
|
Nov 20, 2023 |
|
S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
|
Nov 16, 2023 |
|
S9 Ep41: Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes
|
Nov 13, 2023 |
|
S9 Ep40: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
|
Nov 09, 2023 |
|
S9 Ep39: FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
|
Nov 06, 2023 |
|
S9 Ep38: Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
|
Oct 30, 2023 |
|
S9 Ep37: Naumann Discusses Notable Research Efforts in Endometrial Cancer
|
Oct 26, 2023 |
|
S9 Ep36: Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
|
Oct 23, 2023 |
|
S9 Ep35: Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship
|
Oct 19, 2023 |
|
S9 Ep34: FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia
|
Oct 16, 2023 |
|
S9 Ep33: Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
|
Oct 12, 2023 |
|
S9 Ep32: Expert Insights on the United States Chemotherapy Shortage
|
Oct 09, 2023 |
|
S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
|
Oct 05, 2023 |
|
S9 Ep30: Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
|
Oct 02, 2023 |
|
S9 Ep29: Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
|
Sep 28, 2023 |
|
S9 Ep28: FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
|
Sep 21, 2023 |
|
S9 Ep27: Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST
|
Sep 18, 2023 |
|
S9 Ep26: Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer
|
Sep 14, 2023 |
|
S9 Ep25: Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities
|
Sep 11, 2023 |
|
S9 Ep24: FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
|
Sep 07, 2023 |
|
S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
|
Sep 04, 2023 |
|
S9 Ep22: Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC
|
Aug 31, 2023 |
|
S9 Ep21: FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
|
Aug 28, 2023 |
|
S9 Ep20: FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML
|
Aug 21, 2023 |
|
S9 Ep19: Trent Breaks Down Mutation Testing and ctDNA Monitoring in GIST
|
Aug 17, 2023 |
|
S9 Ep18: Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML
|
Aug 14, 2023 |
|
S9 Ep17: Sanai Spotlights Meningioma Symptoms, Treatment Options, and Research Needs
|
Aug 10, 2023 |
|
S9 Ep16: Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
|
Aug 07, 2023 |
|
S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
|
Aug 03, 2023 |
|
S9 Ep14: Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST
|
Jul 31, 2023 |
|
S9 Ep13: Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL
|
Jul 24, 2023 |
|
S9 Ep12: Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer
|
Jul 20, 2023 |
|
S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
|
Jul 17, 2023 |
|
S9 Ep10: Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management
|
Jul 13, 2023 |
|
S9 Ep9: FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis
|
Jul 10, 2023 |
|
S9 Ep8: King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer
|
Jul 06, 2023 |
|
S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis
|
Jul 03, 2023 |
|
S9 Ep6: Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023
|
Jun 29, 2023 |
|
S9 Ep5: Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care
|
Jun 22, 2023 |
|
S9 Ep4: Reuss Reviews the Development of LP-300 in Advanced NSCLC
|
Jun 19, 2023 |
|
S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
|
Jun 15, 2023 |
|
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
|
Jun 12, 2023 |
|
S9 Ep1: Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research
|
Jun 08, 2023 |
|
S8 Ep50: Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology
|
Jun 05, 2023 |
|
S8 Ep49: Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML
|
May 29, 2023 |
|
S8 Ep48: Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid Tumors
|
May 25, 2023 |
|
S8 Ep47: Mutale Discusses Disparities in Cancer Clinical Trial Eligibility, Access and Enrollment
|
May 22, 2023 |
|
S8 Ep46: Oncology Professionals Explain the Nuances of Career-Building Mentorship and Self-Advocacy
|
May 18, 2023 |
|
S8 Ep45: FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant
|
May 15, 2023 |
|
S8 Ep44: Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate
|
May 11, 2023 |
|
S8 Ep43: Ehrhardt Explains the Effects of Modifiable Health Conditions on Late Mortality for Childhood Cancer Survivors
|
May 08, 2023 |
|
S8 Ep41: Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials
|
May 01, 2023 |
|
S8 Ep40: Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer
|
Apr 27, 2023 |
|
S8 Ep39: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
|
Apr 24, 2023 |
|
S8 Ep38: Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer
|
Apr 20, 2023 |
|
S8 Ep37: Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience
|
Apr 17, 2023 |
|
S8 Ep36: FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer
|
Apr 13, 2023 |
|
S8 Ep35: Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates
|
Apr 10, 2023 |
|
S8 Ep34: Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management
|
Apr 06, 2023 |
|
S8 Ep33: Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer
|
Apr 03, 2023 |
|
S8 Ep32: FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer
|
Mar 30, 2023 |
|
S8 Ep31: Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration
|
Mar 27, 2023 |
|
S8 Ep29: FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
|
Mar 20, 2023 |
|
S8 Ep28: Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC
|
Mar 16, 2023 |
|
S8 Ep27: Milner, Dalal, and Ligon Discuss Stem Cell Transplant Methods, Results, and Risk Factors in Pediatric Patients
|
Mar 13, 2023 |
|
S8 Ep26: FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
|
Mar 09, 2023 |
|
S8 Ep25: CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice
|
Mar 06, 2023 |
|
S8 Ep24: Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma
|
Mar 02, 2023 |
|
S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL
|
Feb 27, 2023 |
|
S8 Ep22: Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management
|
Feb 23, 2023 |
|
S8 Ep21: FDA Approval Insights: Zanubrutinib in CLL and SLL
|
Feb 16, 2023 |
|
S8 Ep20: Small and Reagan Review Tumor Lysis Syndrome Risk Factors and Management Strategies
|
Feb 13, 2023 |
|
S8 Ep19: D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
|
Feb 09, 2023 |
|
S8 Ep19: FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC
|
Feb 06, 2023 |
|
S8 Ep18: Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma
|
Feb 02, 2023 |
|
S8 Ep17: Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer
|
Jan 30, 2023 |
|
S8 Ep17: FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
|
Jan 26, 2023 |
|
S8 Ep16: Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer
|
Jan 23, 2023 |
|
S8 Ep15: Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC
|
Jan 19, 2023 |
|
S8 Ep14: Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer
|
Jan 16, 2023 |
|
S8 Ep14: Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL
|
Jan 12, 2023 |
|
S8 Ep12: Breast Cancer Experts Review HR+ Treatment Updates From SABCS 2022
|
Jan 05, 2023 |
|
S8 Ep11: Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates
|
Jan 02, 2023 |
|
S8 Ep10: Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
|
Dec 29, 2022 |
|
S8 Ep9: Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer
|
Dec 26, 2022 |
|
S8 Ep8: Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment
|
Dec 22, 2022 |
|
S8 Ep7: Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma
|
Dec 19, 2022 |
|
S8 Ep6: FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
|
Dec 15, 2022 |
|
S8 Ep5: Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
|
Dec 12, 2022 |
|
S8 Ep4: Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL
|
Dec 08, 2022 |
|
S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
|
Dec 05, 2022 |
|
S8 Ep2: Leone Lays Out Research Needs and Treatment Approaches in Male Breast Cancer
|
Dec 01, 2022 |
|
S8 Ep1: Florez Discusses Crucial Aspects of Cancer Care Equity and Survivorship
|
Nov 28, 2022 |
|
S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC
|
Nov 24, 2022 |
|
S7 Ep49: Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time
|
Nov 21, 2022 |
|
S7 Ep48: Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality
|
Nov 17, 2022 |
|
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
|
Nov 14, 2022 |
|
S7 Ep46: Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022
|
Nov 10, 2022 |
|
S7 Ep45: Sauter and Hill Talk Through CAR T Cell Sequencing and Access in Lymphomas
|
Nov 07, 2022 |
|
S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
|
Nov 03, 2022 |
|
S7 Ep43: Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding
|
Oct 31, 2022 |
|
S7 Ep42: Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care
|
Oct 27, 2022 |
|
S7 Ep41: FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors
|
Oct 24, 2022 |
|
S7 Ep40: Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia
|
Oct 20, 2022 |
|
S7 Ep39: Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC
|
Oct 17, 2022 |
|
S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
|
Oct 13, 2022 |
|
S7 Ep37: Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
|
Oct 10, 2022 |
|
S7 Ep36: Velcheti Discusses Mobile Telehealth-Based Research to Close Cancer Care Gaps
|
Oct 06, 2022 |
|
S7 Ep35: FDA Approval Insights: Durvalumab Plus Gemcitabine and Cisplatin in Biliary Tract Cancer
|
Oct 03, 2022 |
|
S7 Ep34: Shepard Discusses Symptoms, Management, and Future Directions in Desmoid Tumors
|
Sep 29, 2022 |
|
S7 Ep33: Deol on the Importance of a Well-Rounded Fellowship Experience
|
Sep 26, 2022 |
|
S7 Ep32: Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders
|
Sep 22, 2022 |
|
S7 Ep31: FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
|
Sep 19, 2022 |
|
S7 Ep30: Leal Sheds Light on Symptoms and Treatment of Lambert-Eaton Myasthenic Syndrome
|
Sep 15, 2022 |
|
S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC
|
Sep 12, 2022 |
|
S7 Ep28: Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma
|
Sep 08, 2022 |
|
S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
|
Sep 05, 2022 |
|
S7 Ep27: Iams and Shah Break Down Lambert-Eaton Myasthenic Syndrome in SCLC and Other Neuroendocrine Cancers
|
Sep 01, 2022 |
|
S7 Ep26: Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors
|
Aug 29, 2022 |
|
S7 Ep25: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC
|
Aug 25, 2022 |
|
S7 Ep24: Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer
|
Aug 22, 2022 |
|
S7 Ep24: Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates
|
Aug 18, 2022 |
|
S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
|
Aug 15, 2022 |
|
S7 Ep22: Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
|
Aug 11, 2022 |
|
S7 Ep21: Leukemia Experts Reflect on Defining Moments as Women in the Field
|
Aug 08, 2022 |
|
S7 Ep20: Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes
|
Aug 04, 2022 |
|
S7 Ep19: Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
|
Aug 01, 2022 |
|
S7 Ep18: FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
|
Jul 28, 2022 |
|
S7 Ep17: Wagner Weighs In On Research and Development in Angiosarcoma
|
Jul 25, 2022 |
|
S7 Ep16: FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
|
Jul 21, 2022 |
|
S7 Ep15: Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
|
Jul 18, 2022 |
|
S7 Ep14: Jain Discusses the Driving Forces of Gender Inequities in Medicine
|
Jul 14, 2022 |
|
S7 Ep13: Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer
|
Jul 11, 2022 |
|
S7 Ep12: Research Reflections: Tarantino Talks Through the Implications of ASCO 2022 Data in Breast Cancer
|
Jul 07, 2022 |
|
S7 Ep11: Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)
|
Jul 04, 2022 |
|
S7 Ep10: Duma Discusses the Unique Challenges of Women With Lung Cancer
|
Jun 30, 2022 |
|
S7 Ep9: Leukemia Pioneers Chronicle Career Experiences and Milestones
|
Jun 27, 2022 |
|
S7 Ep8: Khan Casts Light on Disparities in Surgical Care of GI Tract Cancer
|
Jun 23, 2022 |
|
S7 Ep7: Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer
|
Jun 20, 2022 |
|
S7 Ep6: Lee Lays Out Treatment Developments in Non–Clear Cell RCC
|
Jun 16, 2022 |
|
S7 Ep5: Ueno Underscores the Importance of Accurate Diagnoses and Novel Treatments in IBC
|
Jun 13, 2022 |
|
S7 Ep4: Hua Highlights Innovative Research With Immunotherapy in NETs
|
Jun 09, 2022 |
|
S7 Ep3: Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
|
Jun 06, 2022 |
|
S7 Ep2: Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients
|
Jun 02, 2022 |
|
S7 Ep1: Karmanos Faculty Share Experiences and Career Insights as Women in Oncology
|
May 30, 2022 |
|
S6 Ep50: Tarantino Previews Exciting Research in HER2-Low Breast Cancer
|
May 26, 2022 |
|
S6 Ep49: Taylor Provides Insight Into Pirtobrutinib Resistance in CLL
|
May 23, 2022 |
|
S6 Ep48: Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma
|
May 19, 2022 |
|
S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC
|
May 16, 2022 |
|
S6 Ep46: Pegram Expounds on Exciting Developments in HER2+ Metastatic Breast Cancer
|
May 12, 2022 |
|
S6 Ep45: Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC
|
May 09, 2022 |
|
S6 Ep44: Borgen Recommends Revamping Peer Review for a Post-COVID-19 World
|
May 05, 2022 |
|
S6 Ep43: FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma
|
May 02, 2022 |
|
S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
|
Apr 28, 2022 |
|
S6 Ep41: Bardia Reflects on Important Data in HER2+ Breast Cancer
|
Apr 21, 2022 |
|
S6 Ep40: D'Abreo Addresses AEs in Metastatic Breast Cancer Care
|
Apr 14, 2022 |
|
S6 Ep39: Tripathy on Treating HER2+ Breast Cancer With Leptomeningeal Metastasis
|
Apr 07, 2022 |
|
S6 Ep38: FDA Approval Insights: Pacritinib in Myelofibrosis
|
Mar 31, 2022 |
|
S6 Ep37: Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022
|
Mar 24, 2022 |
|
S6 Ep36: Lyle and Patel Examine Diagnostic and Management Paradigms in MDS
|
Mar 17, 2022 |
|
S6 Ep35: Ross Reflects on Surgical Advances and Changing Trends in CRC
|
Mar 10, 2022 |
|
S6 Ep35: Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer
|
Mar 03, 2022 |
|
S6 Ep34: Jain Talks Patient Management, Dosing, and Toxicity Mitigation With Frontline PARP Maintenance in Ovarian Cancer
|
Feb 24, 2022 |
|
S6 Ep28: Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
|
Feb 17, 2022 |
|
S6 Ep33: Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies
|
Feb 10, 2022 |
|
S6 Ep32: Simon Shares Steps Towards Bridging Clinical Trial Disparities in Cancer
|
Feb 07, 2022 |
|
S6 Ep31: Rare Cancers Report: Pediatric Neuroblastoma
|
Feb 03, 2022 |
|
S6 Ep30: Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia
|
Jan 31, 2022 |
|
S6 Ep29: Sorting Through Sexism, Guilt, and Motherhood in Medicine
|
Jan 27, 2022 |
|
S6 Ep27: Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management
|
Jan 20, 2022 |
|
S6 Ep26: Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL
|
Jan 17, 2022 |
|
S6 Ep25: Basu on Getting Ahead of the Shadow Curve of COVID-19 in Oncology
|
Jan 13, 2022 |
|
S6 Ep24: Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma
|
Jan 10, 2022 |
|
S6 Ep23: Dietz Draws Attention to Gender Disparities in Breast Cancer
|
Jan 06, 2022 |
|
S6 Ep22: Gilbert on Gaining New Ground at Vanderbilt
|
Jan 03, 2022 |
|
S6 Ep21: Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC
|
Dec 30, 2021 |
|
S6 Ep21: Gasparetto Talks Management Strategies for Belantamab Mafodotin–Related Ocular Toxicity in Myeloma
|
Dec 27, 2021 |
|
S6 Ep20: Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL
|
Dec 23, 2021 |
|
S6 Ep19: Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer
|
Dec 20, 2021 |
|
S6 Ep18: Hochster Underscores Headway Made in Gastric/GEJ Cancers
|
Dec 16, 2021 |
|
S6 Ep17: Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies
|
Dec 13, 2021 |
|
S6 Ep16: Coombs Previews Anticipated ASH Abstracts in CLL
|
Dec 09, 2021 |
|
S6 Ep15: FDA Approval Insights: Adjuvant Pembrolizumab in RCC
|
Dec 06, 2021 |
|
S6 Ep14: Bleicher and Nardello Talk About Finding the Best Fit for Fellowship in Oncology
|
Dec 02, 2021 |
|
S6 Ep13: Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma
|
Nov 29, 2021 |
|
S6 Ep12: Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer
|
Nov 25, 2021 |
|
S6 Ep11: Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson
|
Nov 22, 2021 |
|
S6 Ep10: Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
|
Nov 18, 2021 |
|
S6 Ep9: Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer
|
Nov 15, 2021 |
|
S6 Ep8: Gradishar Gives Insight Into the Growing Role of SERDs in Breast Cancer
|
Nov 11, 2021 |
|
S6 Ep7: Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer
|
Nov 08, 2021 |
|
S6 Ep6: Yarchoan Talks Research Directions in Fibrolamellar Carcinoma
|
Nov 04, 2021 |
|
S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL
|
Nov 01, 2021 |
|
S6 Ep4: Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases
|
Oct 28, 2021 |
|
S6 Ep3: Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC
|
Oct 25, 2021 |
|
S6 Ep2: Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
|
Oct 21, 2021 |
|
S6 Ep1: Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers
|
Oct 18, 2021 |
|
S5 Ep50: Gordan on Growing the Infrastructure for In-House Genomic Testing
|
Oct 14, 2021 |
|
S5 Ep49: DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
|
Oct 11, 2021 |
|
S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
|
Oct 07, 2021 |
|
S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
|
Oct 04, 2021 |
|
S5 Ep46: Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
|
Sep 30, 2021 |
|
S5 Ep45: Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
|
Sep 27, 2021 |
|
S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer
|
Sep 23, 2021 |
|
S5 Ep43: Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC
|
Sep 20, 2021 |
|
S5 Ep42: Neel on Maximizing Research Strides in Oncology
|
Sep 16, 2021 |
|
S5 Ep41: Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer
|
Sep 13, 2021 |
|
S5 Ep40: Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer
|
Sep 09, 2021 |
|
S5 Ep39: McKay Filters Through Frontline Treatment Considerations in mRCC
|
Sep 06, 2021 |
|
S5 Ep38: Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
|
Sep 02, 2021 |
|
S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS
|
Aug 30, 2021 |
|
S5 Ep36: FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer
|
Aug 26, 2021 |
|
S5 Ep35: Krie and Yuan Talk Toxicity Management in Breast Cancer
|
Aug 23, 2021 |
|
S5 Ep34: DFCI Faculty Relay Insight Into Confirmed Rebounds of Cancer Screenings After COVID-19
|
Aug 19, 2021 |
|
S5 Ep33: Chachoua on Leveraging Screening Opportunities in Lung Cancer
|
Aug 16, 2021 |
|
S5 Ep32: Making the Most of Molecular Testing in Breast Cancer
|
Aug 12, 2021 |
|
S5 Ep31: FDA Approval Insights: Isatuximab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
|
Aug 09, 2021 |
|
S5 Ep30: Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting
|
Aug 05, 2021 |
|
S5 Ep29: Rariy Reviews In-Home Infusion Initiative in Oncology
|
Aug 02, 2021 |
|
S5 Ep28: Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers
|
Jul 29, 2021 |
|
S5 Ep27: Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer
|
Jul 26, 2021 |
|
S5 Ep26: FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer
|
Jul 22, 2021 |
|
S5 Ep25: Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL
|
Jul 19, 2021 |
|
S5 Ep24: Mayer on the Optimization of SERDs in ER+ Breast Cancer
|
Jul 15, 2021 |
|
S5 Ep23: Wainberg Weighs In on Advances in HER2+ GI Cancers
|
Jul 12, 2021 |
|
S5 Ep22: CTCA Leaders Provide Post-Pandemic Predictions in Oncology
|
Jul 08, 2021 |
|
S5 Ep21: Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers
|
Jul 05, 2021 |
|
S5 Ep20: Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer
|
Jul 01, 2021 |
|
S5 Ep19: Lee-Kim on Fostering a Fulfilling Fellowship in Oncology
|
Jun 28, 2021 |
|
S5 Ep18: Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer
|
Jun 24, 2021 |
|
S5 Ep17: Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19
|
Jun 21, 2021 |
|
S5 Ep16: George Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer Pipeline
|
Jun 17, 2021 |
|
S5 Ep15: Pant Projects an Expanding Role for Targeted Therapy in Pancreatic Cancer
|
Jun 14, 2021 |
|
S5 Ep14: Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma
|
Jun 10, 2021 |
|
S5 Ep13: FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
|
Jun 07, 2021 |
|
S1 Ep1: FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC
|
Jun 03, 2021 |
|
S5 Ep12: Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma
|
May 31, 2021 |
|
S5 Ep11: Baumann Characterizes the Current Treatment Landscape of Merkel Cell Carcinoma
|
May 27, 2021 |
|
S5 Ep10: Kaklamani Speaks to a Shifting HER2+ Breast Cancer Paradigm
|
May 24, 2021 |
|
S5 Ep9: UCSD Faculty Contextualize Cases of Cutaneous Squamous Cell Carcinoma
|
May 20, 2021 |
|
S5 Ep8: Grivas and Wright Weigh In on the Benefits of Multidisciplinary Care in Bladder Cancer
|
May 17, 2021 |
|
S5 Ep7: O'Dea Offers Insight Into the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer
|
May 13, 2021 |
|
S5 Ep6: Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
|
May 10, 2021 |
|
S5 Ep5: FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma
|
May 06, 2021 |
|
S5 Ep4: FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma
|
May 03, 2021 |
|
S5 Ep3: Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies
|
Apr 29, 2021 |
|
S5 Ep2: FDA Approval Insights: TheraSphere Y-90 Glass Microspheres in HCC
|
Apr 26, 2021 |
|
S5 Ep1: Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies
|
Apr 22, 2021 |
|
S4 Ep50: Saba Spotlights the Nuances of Treating Nasopharygeal Cancer
|
Apr 19, 2021 |
|
S4 Ep49: Research Reflections: Sonpavde on Urothelial Cancer Updates From the 2021 GU Cancers Symposium
|
Apr 15, 2021 |
|
S4 Ep48: FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma
|
Apr 12, 2021 |
|
S4 Ep47: FDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung Cancer
|
Apr 08, 2021 |
|
S4 Ep46: Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research
|
Apr 05, 2021 |
|
S4 Ep45: The Marshalls Open a Candid Conversation About Cancer
|
Apr 01, 2021 |
|
S4 Ep44: Hu Highlights Recent Advances and Approvals in RET-Altered Thyroid Cancer
|
Mar 29, 2021 |
|
S4 Ep43: Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer
|
Mar 25, 2021 |
|
S4 Ep42: Borgen Breaks Down the Domino Effect of Expanded Education and Banished Stigmas in Male Breast Cancer
|
Mar 22, 2021 |
|
S4 Ep41: Monk and Herzog Hammer Out PARP Nuances in Ovarian Cancer
|
Mar 18, 2021 |
|
S4 Ep40: Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC
|
Mar 16, 2021 |
|
S4 Ep39: Levy Lauds Biomarker-Driven Data in Lung Cancer
|
Mar 11, 2021 |
|
S4 Ep38: FDA Approval Insights: Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer
|
Mar 08, 2021 |
|
S4 Ep37: Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
|
Mar 04, 2021 |
|
S4 Ep36: FDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLC
|
Mar 01, 2021 |
|
S4 Ep35: Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers
|
Feb 25, 2021 |
|
S4 Ep34: Nichols on Navigating the Nuances of von Hippel-Lindau Disease
|
Feb 22, 2021 |
|
S4 Ep33: Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer
|
Feb 18, 2021 |
|
S4 Ep32: Schilsky and Gralow Share Advice for ASCO Leadership and Therapeutic Equity in Cancer
|
Feb 15, 2021 |
|
S4 Ep31: Klempner Keys in on the Pan-Tumor Potential of Seribantumab in NGR1+ Solid Tumors
|
Feb 11, 2021 |
|
S4 Ep30: Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology
|
Feb 08, 2021 |
|
S4 Ep29: Mesa and Gerds Talk Management Strategies and Emerging Agents in Myelofibrosis
|
Feb 04, 2021 |
|
S4 Ep27: Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC
|
Feb 01, 2021 |
|
S4 Ep28: Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC
|
Feb 01, 2021 |
|
S4 Ep26: Markman Talks Vilified Vaccines, Taboos, and Treatment for Cervical Cancer
|
Jan 28, 2021 |
|
S4 Ep25: FDA Approval Insights: Nivolumab/Cabozantinib in Advanced RCC
|
Jan 25, 2021 |
|
S4 Ep24: Forecasting Future Advances Across Oncology
|
Jan 21, 2021 |
|
S4 Ep23: Pursuing New Paradigms in Prostate Cancer
|
Jan 14, 2021 |
|
S4 Ep22: Powles and Rini Put ctDNA Into Perspective in Urothelial Cancer
|
Jan 11, 2021 |
|
S4 Ep21: Braunstein and Richter Talk Transplant and Therapy Options in Newly Diagnosed Myeloma
|
Jan 07, 2021 |
|
S4 Ep20: Spotlighting Management Strategies Across Sarcoma Subtypes
|
Jan 04, 2021 |
|
S4 Ep19: Lindau on Leading Successful Surgical Fellowships
|
Dec 31, 2020 |
|
S4 Ep18: Gaining Insight Into the Management of Gastrointestinal Malignancies
|
Dec 28, 2020 |
|
S4 Ep17: Druker Details a Career of Determination, Patient Impact, and Family Success
|
Dec 24, 2020 |
|
S4 Ep16: Multimodality Therapy Makes Waves in Bladder Cancer
|
Dec 21, 2020 |
|
S4 Ep15: Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC
|
Dec 17, 2020 |
|
S4 Ep14: Learning to Tailor Targeted and Immune Therapy in Lung Cancer
|
Dec 15, 2020 |
|
S4 Ep13: Bardia Brings to Light Complex Breast Cancer Cases
|
Dec 10, 2020 |
|
S4 Ep12: Robert Recaps a Career of Clinical Research in Melanoma
|
Dec 07, 2020 |
|
S4 Ep11: Huntsman Homes in on the Integration of Precision Medicine in Oncology
|
Dec 03, 2020 |
|
S4 Ep10: Marvels in Medicine: Dr. Karlan on Creating Continuous Quality Improvement in Gynecologic Oncology
|
Nov 30, 2020 |
|
S4 Ep9: Loaiza-Bonilla on Applications, Actionability, and Affordability of AI in Oncology
|
Nov 26, 2020 |
|
S4 Ep8: Oxnard on Opening the Door for Precision Medicine in Lung Cancer
|
Nov 23, 2020 |
|
S4 Ep7: Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis
|
Nov 19, 2020 |
|
S4 Ep6: Raez Raises Concerns Over Delayed Cancer Care in the COVID-19 Era
|
Nov 16, 2020 |
|
S4 Ep5: Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer
|
Nov 12, 2020 |
|
S4 Ep4: Aggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer Armamentarium
|
Nov 09, 2020 |
|
S4 Ep3: Tripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast Cancer
|
Nov 06, 2020 |
|
S4 Ep2: Lyman on Bringing Biosimilars From Bench to Bedside in Oncology
|
Nov 02, 2020 |
|
S4 Ep1: Raez on the Rise of Liquid Biopsy in Lung Cancer
|
Oct 29, 2020 |
|
S3 Ep50: FDA Approval Insights: Selinexor in Relapsed/Refractory DLBCL
|
Oct 26, 2020 |
|
S3 Ep49: FDA Approval Insights: Daratumumab/Carfilzomib/Dexamethasone in Myeloma
|
Oct 22, 2020 |
|
S3 Ep48: Gandara Evaluates Opportunities for Virtual Education, Expansion, and Engagement Amid COVID-19
|
Oct 19, 2020 |
|
S3 Ep47: Garcia-Manero Previews Potential New Therapeutic Standards in TP53-Mutated MDS/AML
|
Oct 15, 2020 |
|
S3 Ep46: Gutierrez Provides Insight on Bridging Gaps in Cancer Care Among Hispanic Patients
|
Oct 12, 2020 |
|
S3 Ep45: Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors
|
Oct 08, 2020 |
|
S3 Ep44: O’Regan on Protocols, Best Practices, and Virtual Etiquette for Cancer Care in Light of COVID-19
|
Oct 05, 2020 |
|
S3 Ep43: FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
|
Oct 01, 2020 |
|
S3 Ep42: FDA Approval Insights: Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer
|
Sep 28, 2020 |
|
S3 Ep41: FDA Approval Insights: Lurbinectedin in Metastatic SCLC
|
Sep 24, 2020 |
|
S3 Ep40: Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer
|
Sep 21, 2020 |
|
S3 Ep39: FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma
|
Sep 17, 2020 |
|
S3 Ep38: Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer
|
Sep 14, 2020 |
|
S3 Ep37: Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer
|
Sep 10, 2020 |
|
S3 Ep36: Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
|
Sep 07, 2020 |
|
S3 Ep35: Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer
|
Sep 03, 2020 |
|
S3 Ep34: GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer
|
Aug 31, 2020 |
|
S3 Ep33: FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma
|
Aug 27, 2020 |
|
S3 Ep32: Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era
|
Aug 24, 2020 |
|
S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
|
Aug 20, 2020 |
|
S3 Ep30: Pegram Unpacks Pivotal Data in Breast Cancer
|
Aug 17, 2020 |
|
S3 Ep29: Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma
|
Aug 13, 2020 |
|
S3 Ep28: Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer
|
Aug 10, 2020 |
|
S3 Ep27: Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
|
Aug 06, 2020 |
|
S3 Ep26: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL
|
Aug 03, 2020 |
|
S3 Ep25: DiNardo Discusses VIALE-A and Venetoclax Combo in AML
|
Jul 30, 2020 |
|
S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess
|
Jul 27, 2020 |
|
S3 Ep23: Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC
|
Jul 23, 2020 |
|
S3 Ep22: FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers
|
Jul 20, 2020 |
|
S3 Ep21: Research Reflections: Sarcoma Experts Consider Emerging Evidence for Novel Combos
|
Jul 16, 2020 |
|
S3 Ep20: First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma
|
Jul 13, 2020 |
|
S3 Ep19: Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer
|
Jul 09, 2020 |
|
S3 Ep18: FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC
|
Jul 06, 2020 |
|
S3 Ep17: Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon
|
Jul 02, 2020 |
|
S3 Ep16: Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC
|
Jun 29, 2020 |
|
S3 Ep15: FDA Approval Insights: Olaparib in HRR-Mutant mCRPC
|
Jun 25, 2020 |
|
S3 Ep14: Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer
|
Jun 22, 2020 |
|
S3 Ep13: Integrating Nutrition Into the Continuum of Cancer Care
|
Jun 18, 2020 |
|
S3 Ep12: FDA Approval Insights: Nivolumab/Ipilimumab in Advanced NSCLC
|
Jun 15, 2020 |
|
S3 Ep11: Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer
|
Jun 11, 2020 |
|
S3 Ep10: Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
|
Jun 08, 2020 |
|
S3 Ep9: Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
|
Jun 04, 2020 |
|
S3 Ep8: Chowdhary Covers Risk-Reducing Strategies and Recommendations During the COVID-19 Era
|
Jun 01, 2020 |
|
S3 Ep7: Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology
|
May 28, 2020 |
|
S3 Ep6: Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives
|
May 25, 2020 |
|
S3 Ep5: FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma
|
May 21, 2020 |
|
S3 Ep4: McGregor Details GU Treatment Guidelines During COVID-19 Pandemic
|
May 18, 2020 |
|
S3 Ep3: FDA Approval Insights: Olaparib/Bevacizumab in Advanced Ovarian Cancer
|
May 14, 2020 |
|
S3 Ep2: Talking Tumors: Exploring Management Strategies in Multiple Myeloma
|
May 11, 2020 |
|
S3 Ep1: Making Headway in GI Malignancies in Miami
|
May 07, 2020 |
|
S2 Ep50: The Uromigos Unveil Updates and Insights on the Impact of COVID-19 on GU Cancers
|
May 04, 2020 |
|
S2 Ep49: Marvels in Medicine: Gabriel Hortobagyi on Challenging Historical Dogmas in Breast Cancer
|
Apr 30, 2020 |
|
S2 Ep48: FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
|
Apr 27, 2020 |
|
S2 Ep47: Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio
|
Apr 23, 2020 |
|
S2 Ep46: Talking Tumors: Treating With Immunotherapy and Targeted Therapy in Lung Cancer
|
Apr 20, 2020 |
|
S2 Ep45: Navigating Newfound GU Treatment Considerations in the Context of COVID-19
|
Apr 16, 2020 |
|
S2 Ep44: Physician and Patient Perspectives on Diagnosis and Treatment in Essential Thrombocythemia
|
Apr 13, 2020 |
|
S2 Ep43: Homing in on Clinical Advances in Hematologic Malignancies in Chicago
|
Apr 09, 2020 |
|
S2 Ep42: Gaining Ground in Genitourinary Malignancies in Nashville
|
Apr 06, 2020 |
|
S2 Ep41: Talking HER2-Targeted Therapy With Dr. Ajani
|
Apr 03, 2020 |
|
S2 Ep40: Talking HER2-Targeted Therapy With Dr. Chau
|
Apr 03, 2020 |
|
S2 Ep39: Talking HER2-Targeted Therapy With Dr. Marshall
|
Apr 03, 2020 |
|
S2 Ep38: Talking HER2-Targeted Therapy With Dr. Corcoran
|
Apr 03, 2020 |
|
S2 Ep37: Dr. Marshall Calls for Continued Discourse on Physician Burnout in Oncology
|
Apr 02, 2020 |
|
S2 Ep36: Collaborative Efforts Lead to the Launch of the COVID-19 and Cancer Consortium Registry
|
Mar 30, 2020 |
|
S2 Ep35: FLASCO Faculty Flesh Out Case Studies in GI Cancers
|
Mar 25, 2020 |
|
S2 Ep34: Spotlighting New Standards of Care in Lung Cancer in Summit
|
Mar 18, 2020 |
|
S2 Ep33: Maurie Markman, MD: Confronting the Complexities of Care in Gynecologic Cancers
|
Mar 11, 2020 |
|
S2 Ep32: Navigating NGS and Novel Therapies in GI Malignancies in New York
|
Mar 04, 2020 |
|
S2 Ep31: Talking Tumors: Turning to Liquid Biopsies and Immunotherapy in Lung Cancer
|
Feb 26, 2020 |
|
S2 Ep30: Unpacking IO Innovations in Lung Cancer in Pittsburgh
|
Feb 19, 2020 |
|
S2 Ep29: Jeffrey Weber, MD, PhD: Charting New Territories in Melanoma
|
Feb 12, 2020 |
|
S2 Ep28: Analyzing the Application of Precision Medicine in Austin
|
Feb 05, 2020 |
|
S2 Ep27: Talking Tumors: Contemplating Clinical Conundrums in Lung Cancer
|
Jan 29, 2020 |
|
S2 Ep26: Pondering Progress Made in GU Cancers in Phoenix
|
Jan 23, 2020 |
|
S2 Ep25: Collaboration Saves Lives: Managing irAEs is a "Dynamic Discussion"
|
Jan 17, 2020 |
|
S2 Ep24: Airing Treatment Advances in Breast Cancer in New York
|
Jan 08, 2020 |
|
S2 Ep23: Stephanie Graff, MD: Information Is Power for Patients With Breast Cancer
|
Jan 01, 2020 |
|
S2 Ep22: Outlining Advances Made in Ovarian Cancer in Oklahoma City
|
Dec 25, 2019 |
|
S2 Ep21: Talking Tumors: Weill Cornell Medicine Experts Walk Through Challenging Breast Cancer Cases
|
Dec 19, 2019 |
|
S2 Ep20: Highlighting Progress Made in Hematologic Malignancies in Philly
|
Dec 12, 2019 |
|
S2 Ep19: Checking Out Emerging Approaches in Lung Cancer Treatment in Chicago
|
Dec 04, 2019 |
|
S2 Ep18: Tanios Bekaii-Saab, MD: Not Just Seeing the Light, But Getting Out of the Tunnel
|
Nov 27, 2019 |
|
S2 Ep17: Reviewing Breakthroughs in Breast Cancer in Raleigh
|
Nov 21, 2019 |
|
S2 Ep16: Talking Tumors: Filling Data Gaps in Multiple Myeloma
|
Nov 15, 2019 |
|
S2 Ep15: Spotlighting New Standards in Lung Cancer in Salt Lake City
|
Nov 07, 2019 |
|
S2 Ep14: Howard "Skip" Burris, MD: A Passion for Befriending Patients and Always Being Kind
|
Nov 01, 2019 |
|
S2 Ep13: Outlining Progress Made in Ovarian Cancer in Pittsburgh
|
Oct 24, 2019 |
|
S2 Ep12: Talking Tumors: Adaptive Approaches in Triple-Negative and HR-Positive Breast Cancers
|
Oct 16, 2019 |
|
S2 Ep11: Spreading Newfound Treatment Strategies in Hematologic Malignancies in Seattle
|
Oct 09, 2019 |
|
S2 Ep10: Examining Major Breakthroughs Made in Breast Cancer in Milwaukee
|
Oct 02, 2019 |
|
S2 Ep9: Perusing Progress Made in Ovarian Cancer Treatment Paradigm in Pasadena
|
Sep 23, 2019 |
|
S2 Ep8: Maha Hussain, MD: Anything Is Possible With a Fire in the Belly
|
Sep 18, 2019 |
|
S2 Ep7: Gaining Ground in GI Cancers in Denver
|
Sep 12, 2019 |
|
S2 Ep6: Mapping Multiple Myeloma Advances in NYC
|
Sep 04, 2019 |
|
S2 Ep5: Garnering Breakthroughs in GU Cancers in Boston
|
Aug 29, 2019 |
|
S2 Ep4: Mastering New Advances in Hematologic Malignancies in Milwaukee
|
Aug 20, 2019 |
|
S2 Ep3: Talking Tumors: Leveraging Immunotherapy in Nonsquamous NSCLC
|
Aug 15, 2019 |
|
S2 Ep2: Newfound Understandings of Neuroendocrine Treatment in Kentucky
|
Aug 07, 2019 |
|
S2 Ep1: Perusing Breakthroughs in Breast Cancer in Pasadena
|
Jul 29, 2019 |
|
S1 Ep50: Patrick I. Borgen, MD: From the Wild West of Breast Cancer Research to Chasing Cure
|
Jul 24, 2019 |
|
S1 Ep49: Navigating New Developments in NSCLC in Dallas
|
Jul 20, 2019 |
|
S1 Ep48: Tapping Into Great Progress Made in GI Cancers in Tampa
|
Jul 14, 2019 |
|
S1 Ep47: Hearing About Breakthroughs Made in Hematologic Malignancies in Boston
|
Jun 25, 2019 |
|
S1 Ep46: Discussing Pivotal Progress in Breast Cancer in Dallas
|
Jun 18, 2019 |
|
S1 Ep45: Contemplating Key Updates in GI Cancers in Charlotte
|
Jun 12, 2019 |
|
S1 Ep44: Observing the Latest Developments in Ovarian Cancer in NYC
|
May 30, 2019 |
|
S1 Ep43: Gaining Ground in GI Cancers in Durham
|
May 23, 2019 |
|
S1 Ep42: Examining Key Breast Cancer Updates in Chicago
|
May 15, 2019 |
|
S1 Ep41: Getting Up to Speed On Key Developments in GI Cancers in Washington DC
|
May 08, 2019 |
|
S1 Ep40: Highlighting Pivotal Data From 2018 ASH Annual Meeting
|
May 01, 2019 |
|
S1 Ep39: Talking Tumors: MSK Faculty Highlight Ovarian Cancer Cases
|
Apr 25, 2019 |
|
S1 Ep38: Getting Educated On Advances Made With GI Cancers in Houston
|
Apr 18, 2019 |
|
S1 Ep37: Highlighting Breakthroughs in Breast Cancer in Nashville
|
Apr 10, 2019 |
|
S1 Ep36: Spotlight on Clinical Scenarios in GEJ Cancer
|
Apr 03, 2019 |
|
S1 Ep35: Gaining Insight Into Progress Made With Genitourinary Cancers in Pasadena
|
Mar 27, 2019 |
|
S1 Ep34: Navigating New Advances in Breast Cancer in NYC
|
Mar 20, 2019 |
|
S1 Ep33: Spotlight on Clinical Scenarios in Rectal Adenocarcinoma
|
Mar 15, 2019 |
|
S1 Ep32: Observing the Latest Advances in Ovarian Cancer in Boston
|
Mar 06, 2019 |
|
S1 Ep31: Learning More About Lung Cancer in Kansas City
|
Feb 28, 2019 |
|
S1 Ep30: Getting Up to Speed with Progress Made in GU Cancers in Memphis
|
Feb 20, 2019 |
|
S1 Ep29: Highlighting Headway Made in NSCLC in New York
|
Feb 13, 2019 |
|
S1 Ep28: Examining Breakthroughs Made in Breast Cancer in Minneapolis
|
Feb 06, 2019 |
|
S1 Ep27: Navigating New Advances Made in NSCLC in New York
|
Jan 30, 2019 |
|
S1 Ep26: Making Moves in Multiple Myeloma in NYC
|
Jan 23, 2019 |
|
S1 Ep25: Perusing Progress Made in NSCLC in Washington DC
|
Jan 16, 2019 |
|
S1 Ep24: Talking Treatment Strategies for Breast Cancer in Pittsburgh
|
Jan 09, 2019 |
|
S1 Ep23: Snapshot of the 2018 ASH Annual Meeting in San Diego
|
Jan 04, 2019 |
|
S1 Ep22: Buzzing With News From the San Antonio Breast Cancer Symposium
|
Dec 22, 2018 |
|
S1 Ep21: Exploring Strides Made in Ovarian Cancer & STS in Stanford
|
Dec 19, 2018 |
|
S1 Ep20: Reflecting on New Advances Made in NSCLC in Chicago
|
Dec 05, 2018 |
|
S1 Ep19: Gaining Insight Into Genitourinary Cancers in Charlotte
|
Nov 28, 2018 |
|
S1 Ep18: Keeping Up With Hematologic Advances in Clayton
|
Nov 21, 2018 |
|
S1 Ep17: Getting Educated With GI Cancer Therapies in Newport Beach
|
Nov 14, 2018 |
|
S1 Ep16: Acquiring Lung Cancer Lessons in New Jersey
|
Nov 09, 2018 |
|
S1 Ep15: On the Floor at the 2018 ESMO Congress
|
Oct 31, 2018 |
|
S1 Ep14: Clued in to Hematologic Cancer Treatment in Cleveland
|
Oct 25, 2018 |
|
S1 Ep13: Spreading Awareness of Breast Cancer Advancements With UCSF Faculty
|
Oct 18, 2018 |
|
S1 Ep12: Sharing Insight on Myeloma, CAR T, and More in San Francisco
|
Oct 10, 2018 |
|
S1 Ep11: Tackling Genitourinary Cancer Topics in Chicago
|
Oct 03, 2018 |
|
S1 Ep10: Third Time's a Charm: Sailing to Seattle for More Hematologic Cancer Updates
|
Sep 26, 2018 |
|
S1 Ep9: Diving Into Hematologic Diseases in Dearborn
|
Sep 19, 2018 |
|
S1 Ep8: Taking Lessons From Hematology Experts in Tampa
|
Sep 12, 2018 |
|
S1 Ep7: Learning the Lung Cancer Landscape in Hanover
|
Sep 05, 2018 |
|
S1 Ep6: Obtaining the Latest in Ovarian Cancer in Charlotte
|
Aug 29, 2018 |
|
S1 Ep5: Expanding on Emerging Agents in GI Cancers in Dallas
|
Aug 22, 2018 |
|
S1 Ep4: Navigating Non–Small Cell Lung Cancer Treatment in Charlottesville
|
Aug 15, 2018 |
|
S1 Ep3: Advanced Non–Small Cell Lung Cancer Meeting in Denver
|
Aug 08, 2018 |
|
S1 Ep2: Breast Cancer Meeting in Houston
|
Jul 24, 2018 |
|
S1 Ep1: 2018 ASCO Annual Meeting Recap in Kansas City
|
Jul 10, 2018 |